LAVA Therapeutics (LVTX) Projected to Post Quarterly Earnings on Wednesday

LAVA Therapeutics (NASDAQ:LVTX) is anticipated to post its quarterly earnings results before the market opens on Wednesday, March 19th. Analysts expect LAVA Therapeutics to post earnings of ($0.32) per share and revenue of $2.40 million for the quarter.

LAVA Therapeutics Stock Performance

NASDAQ LVTX opened at $1.31 on Tuesday. The stock has a market capitalization of $34.45 million, a PE ratio of -1.27 and a beta of 0.48. The stock has a 50-day simple moving average of $1.07 and a 200 day simple moving average of $1.39. LAVA Therapeutics has a twelve month low of $0.85 and a twelve month high of $4.21.

Analysts Set New Price Targets

Several research firms have issued reports on LVTX. Leerink Partnrs lowered shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. HC Wainwright reaffirmed a “neutral” rating and set a $1.50 price objective (down previously from $2.00) on shares of LAVA Therapeutics in a report on Thursday, February 27th. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 price target (down from $11.00) on shares of LAVA Therapeutics in a report on Thursday, December 12th. Citizens Jmp downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. Finally, JMP Securities reaffirmed a “market perform” rating and issued a $6.00 target price on shares of LAVA Therapeutics in a research note on Wednesday, December 11th. Five investment analysts have rated the stock with a hold rating, According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $3.17.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.